Targeted Protein Degradation – Talk Bio

Actionable Insights Powered by AI

Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion to Add RIPTAC Cancer Drug Platform

3 weeks ago talkbio0Tagged Acquisition, clinical pipeline, Halda Therapeutics, HLD-0915, Johnson & Johnson, Malignant neoplasm of prostate, Neoplasms, RIPTAC, Targeted Protein Degradation

Johnson & Johnson; Halda Therapeutics; acquisition; RIPTAC; HLD-0915; prostate cancer; targeted protein degradation; oncology; clinical pipeline

Merck KGaA Bolsters Protein Degradation Pipeline with $756M C4 Therapeutics Partnership

2 years ago talkbio0Tagged C4 Therapeutics, Collaboration, Low-Double Digit Tiered Royalties, Merck KGaA, mid-single, Milestone, oncogenic proteins, Targeted Protein Degradation, TORPEDO® Platform, upfront payment

Merck KGaA, C4 Therapeutics, Targeted Protein Degradation, Collaboration, $756M Deal, Oncogenic Proteins, TORPEDO® Platform, Mid-Single to Low-Double Digit Tiered Royalties, Upfront Payment: $16 Million, Potential Milestone Payments: Up to $740 Million